Education and Training
AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN (AVERT™)
The Osprey Medical AVERT System is indicated to reduce contrast media (CM) exposure to the kidneys during percutaneous coronary procedures thereby reducing the risk of contrast induced nephropathy (CIN).
Stanford is currently not accepting patients for this trial.